Use of direct-acting antiviral agents in hepatitis C virusinfected liver transplant candidates
Use of direct-acting antiviral agents in hepatitis C virus-infected liver transplant candidates作者机构：Division of Gastroenterology and HepatologyUniversity of Tennessee Health Sciences CenterMemphisTN 38104United States Division of Gastroenterology and HepatologyStanford University School of MedicineStanfordCA 94304United States Drexel University College of MedicinePhiladelphiaPA 19129United States Department of MedicineSanta Clara Valley Medical CenterSan JoseCA 95128United States
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2018年第24卷第3期
页 面：315-322页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
主 题：Hepatitis C virus Direct-acting antiviral therapy Liver transplantation Purgatory Model for End-stage liver disease Sustained virological response
摘 要：Since the advent of direct acting antiviral(DAA) agents, chronic hepatitis C virus(HCV) treatment has evolved at a rapid pace. In contrast to prior regimen involving ribavirin and pegylated interferon, these newer agents are highly effective, well-tolerated, have shorter course of therapy and safer essentially in all HCV patients including those with advanced liver disease and following liver transplantation. Clinicians caring for HCV-infected patients on the liver transplant(LT) waitlist are often faced with a dilemma whether to treat HCV infection before or after liver transplantation. Sustained virological response(SVR) rates following HCV treatment may improve hepatic function sufficiently enough to negate the need for LT in certain patients. On the other hand, the decrease in MELD without improvement in quality of life in certain patients may lead to delay or dropout from potentially curative LT surgery list. In this context, our review focuses on the approach to and optimal timing of DAA-based treatment of HCV infection in LT candidates in the peri-transplant period.
维普期刊数据库